☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
zai lab
Zai Lab Highlights the Data from P-Ia/Ib Trial of ZL-1310 for Treating Extensive-Stage Small Cell Lung Cancer at ENA Symposium 202...
October 24, 2024
Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis
July 16, 2024
Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired a...
May 20, 2024
Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)
May 13, 2024
Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer
June 7, 2023
Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopeni...
May 6, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.